menthol has been researched along with Colicky Pain in 3 studies
Menthol: A monoterpene cyclohexanol produced from mint oils.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the efficacy of the combined use of L-menthol spraying (L-mentholS) as an antispasmodic agent and carbon dioxide insufflation (CO2I) on the adenoma detection rate (ADR) in a prospective, single-center trial with a 2 × 2 factorial design." | 9.34 | Effects of L-Menthol and Carbon Dioxide on the Adenoma Detection Rate during Colonoscopy: L-Menthol and Carbon Dioxide on Colonoscopy. ( Endo, Y; Inoue, K; Itoh, Y; Kagawa, K; Katayama, T; Komaki, T; Minagawa, Y; Nagata, A; Naito, Y; Nakamura, H; Oka, K; Okuda, T; Ota, T; Sugino, S; Tsuji, T; Yasue, C, 2020) |
| "We examined the efficacy of the combined use of L-menthol spraying (L-mentholS) as an antispasmodic agent and carbon dioxide insufflation (CO2I) on the adenoma detection rate (ADR) in a prospective, single-center trial with a 2 × 2 factorial design." | 5.34 | Effects of L-Menthol and Carbon Dioxide on the Adenoma Detection Rate during Colonoscopy: L-Menthol and Carbon Dioxide on Colonoscopy. ( Endo, Y; Inoue, K; Itoh, Y; Kagawa, K; Katayama, T; Komaki, T; Minagawa, Y; Nagata, A; Naito, Y; Nakamura, H; Oka, K; Okuda, T; Ota, T; Sugino, S; Tsuji, T; Yasue, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Shulman, RJ | 1 |
| Chumpitazi, BP | 1 |
| Abdel-Rahman, SM | 1 |
| Garg, U | 1 |
| Musaad, S | 1 |
| Kearns, GL | 1 |
| Weerts, ZZRM | 1 |
| Keszthelyi, D | 1 |
| Vork, L | 1 |
| Aendekerk, NCP | 1 |
| Frijlink, HW | 1 |
| Brouwers, JRBJ | 1 |
| Neef, C | 1 |
| Jonkers, DMAE | 1 |
| Masclee, AAM | 1 |
| Inoue, K | 1 |
| Okuda, T | 1 |
| Oka, K | 1 |
| Sugino, S | 1 |
| Endo, Y | 1 |
| Ota, T | 1 |
| Minagawa, Y | 1 |
| Yasue, C | 1 |
| Tsuji, T | 1 |
| Katayama, T | 1 |
| Nakamura, H | 1 |
| Nagata, A | 1 |
| Komaki, T | 1 |
| Naito, Y | 1 |
| Itoh, Y | 1 |
| Kagawa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain[NCT03295747] | Phase 1 | 30 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery[NCT02716285] | Phase 3 | 190 participants (Actual) | Interventional | 2016-08-17 | Completed | ||
| A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Heal[NCT02291445] | Phase 2 | 8 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the plasma concentration-time curve from t=0 hrs until t=24 hrs. (NCT02291445)
Timeframe: 24 hours
| Intervention | ug*h/L (Median) |
|---|---|
| Ileocolonic Release PO | 2331 |
| Small Intestinal Release PO | 2623 |
Menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) peak plasma concentrations (NCT02291445)
Timeframe: 24 hours
| Intervention | ug/L (Median) |
|---|---|
| Ileocolonic Release PO | 563.6 |
| Small Intestinal Release PO | 702 |
Time until a measurable plasma concentration of menthol-glucuronide occurs after oral administration of peppermint oil (45ug/L) (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 225 |
| Small Intestinal Release PO | 37 |
Time to reach maximum menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) concentration in plasma (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 360 |
| Small Intestinal Release PO | 180 |
elimination half-life; time required for the plasma concentration of menthol-glucuronide to reach half of its original value. (NCT02291445)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Ileocolonic Release PO | 6.1 |
| Small Intestinal Release PO | 7.7 |
3 trials available for menthol and Colicky Pain
| Article | Year |
|---|---|
Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain.
Topics: Abdominal Pain; Child; Humans; Intestine, Small; Mentha piperita; Menthol; Plant Oils | 2022 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
Effects of L-Menthol and Carbon Dioxide on the Adenoma Detection Rate during Colonoscopy: L-Menthol and Carbon Dioxide on Colonoscopy.
Topics: Abdominal Pain; Adenoma; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Colonoscopy; Colorectal Neo | 2020 |